Emerging risks | Growth Opportunities | APAC Insurance

Friday, November 20, 2026

Regulatory scrutiny, shareholder objections delay Woori’s Tongyang Life delisting plan — report

Regulatory scrutiny and minority shareholder opposition are raising questions over valuation and deal fairness.
June 30, 2026

 • 

3 min read
(Re)in AsiaSIRC 2026 Hub(Re)in AsiaSIRC 2026HubExplore the hub →

Unlock this insight for free

Register for a free 14-day trial to read the full insight.

  • 14 days of access to (Re)in Asia’s premium intelligence
  • Free daily briefing in your inbox each morning
  • No credit card required
(Re)in AsiaSIRC 2026 Hub(Re)in AsiaSIRC 2026HubExplore the hub →